AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Core Viewpoint - AnaptysBio's shares dropped 14% in premarket trading following lawsuits filed against each other by AnaptysBio and Tesaro, a subsidiary of GSK, both alleging breach of contract [1] Company Summary - AnaptysBio is a U.S. drug developer that is currently involved in legal disputes with Tesaro [1] - The lawsuits indicate significant tensions between the two companies, potentially impacting their business relationships and future collaborations [1] Industry Summary - The legal actions reflect broader issues within the pharmaceutical industry regarding contract disputes and partnerships, which can lead to volatility in stock prices [1]